Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK.LN)

Glaxosmithkline Plc (GSK.LN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 89,681,311
  • Shares Outstanding, K 5,030,000
  • Annual Sales, $ 34,114 M
  • Annual Income, $ 4,385 M
  • 60-Month Beta N/A
  • Price/Sales 2.45
  • Price/Cash Flow 8.80
  • Price/Book 5.54
Trade GSK.LN with:
  • Price/Earnings ttm 17.48
  • Earnings Per Share ttm 1.01
  • Most Recent Earnings 0.36 on 04/27/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.56 (4.25%)
  • Most Recent Dividend 0.140 on 05/19/22
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,703.000 +3.58%
on 05/12/22
1,817.000 -2.92%
on 04/29/22
+23.200 (+1.33%)
since 04/20/22
3-Month
1,445.400 +22.04%
on 03/07/22
1,817.000 -2.92%
on 04/29/22
+197.000 (+12.57%)
since 02/18/22
52-Week
1,328.200 +32.81%
on 05/27/21
1,817.000 -2.92%
on 04/29/22
+404.000 (+29.71%)
since 05/20/21

Most Recent Stories

More News
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+

According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t...

GSK : 44.52 (+2.20%)
GSK.LN : 1,764.000 (+1.87%)
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi B.V. as shareholders, today announced that the US Food and Drug Administration...

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
ViiV Healthcare Announces Label Update for Its Long-Acting HIV Treatment, Cabenuva (cabotegravir, rilpivirine), to Be Initiated With or Without an Oral Lead-in Period

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration...

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
Inside Gilead's Lackluster $7.2 Billion Q4 Earnings

Why are investors unenthused with the biotech giant's earnings report?

GILD : 63.84 (+0.90%)
JUNO : 86.96 (+0.10%)
CELG : 108.24 (+0.10%)
BMY : 76.19 (+0.30%)
GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
RCUS : 18.92 (+2.27%)
Tracking Gilead's 4 Big Stories and a Lawsuit in 2022

How will the cost of a settlement affect Gilead's profits over the foreseeable future?

GILD : 63.84 (+0.90%)
GSK.LN : 1,764.000 (+1.87%)
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows

Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis commissioned...

GSK : 44.52 (+2.20%)
GSK.LN : 1,764.000 (+1.87%)
Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination

Pervasive stigma and prejudice towards people living with HIV continues to persist, according to a new international survey released today on World AIDS Day. Funded by ViiV Healthcare, the global specialist...

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
SSTK : 58.97 (-0.99%)
ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

For media and investors only

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings

For media and investors only

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)
Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040

ViiV Healthcare today announced the release of Achieving health equity: a roadmap to eliminating disparities , a new report conducted by Economist Impact , a division of The Economist Group, that explores...

GSK.LN : 1,764.000 (+1.87%)
PFE : 52.47 (+3.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1,806.933
2nd Resistance Point 1,789.467
1st Resistance Point 1,776.733
Last Price 1,764.000
1st Support Level 1,746.533
2nd Support Level 1,729.067
3rd Support Level 1,716.333

See More

52-Week High 1,817.000
Last Price 1,764.000
Fibonacci 61.8% 1,630.278
Fibonacci 50% 1,572.600
Fibonacci 38.2% 1,514.922
52-Week Low 1,328.200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar